Cepheid Eyes Expansion in HAI Test Market as MRSA Assay Helps Drive Q2 Revenue Growth | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Cepheid this week posted a 37 percent increase in second-quarter revenues driven by a 165 percent increase in revenues from clinical products, particularly its molecular diagnostic assay for methicillin-resistant Staphylococcus aureus (MRSA).
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.